sponsored
PatientsVille.com Logo

PatientsVille

Infective Medical Research Studies

Up-to-date List of Infective Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Infective Medical Research Studies

Rank Status Study
1 Unknown  Rationale, Design and Methods for the Early Surgery in Infective Endocarditis Study (ENDOVAL)
Condition: Infective Endocarditis
Interventions: Procedure: Cardiac surgery;   Procedure: State-to-the-art treatment
Outcome Measures: In-hospital mortality rate in high-risk patients with active Infective endocarditis between an early surgical approach and the state-of-the-art treatment in this disease.;   One year mortality rate in high-risk patients with active Infective endocarditis between an early surgical approach and the state-of-the-art treatment in this disease.
2 Unknown  Cardiac Computarized Tomography in Infective Endocarditis
Condition: Infective Endocarditis
Intervention: Device: Cardiac CT 0BRILLIANT 64
Outcome Measures: The diagnostic capacity of cardiac CT in comparison with TEE in the diagnosis of Infective endocarditis;   Assessment of cardiac function in patients with Infective endocarditis
3 Not yet recruiting Infective Endocarditis in Developing Countries, a Prospective, Observational, Multicentre Study
Condition: Infective Endocarditis
Intervention:
Outcome Measures: Mortality at 1 month follow-up;   Mortality at 6 months follow-up
4 Recruiting Impact of Therapeutic Drug Monitoring on Anti-Infective Agents Amongst Severely Burned Patients Requiring ICU Admission
Condition: Burn
Intervention: Other: Systematic Therapeutic Drug Monitoring for the intervention group
Outcome Measures: Time required to achieve anti-Infective plasma concentrations in the target;   Numbers of concentrations within the target during an anti-Infective agents course;   Anti-Infective agents consumption;   Development of antibiotic resistance;   Length of ICU stay based on TBSA;   Characterization of the pharmacokinetic profile of most widely used antibiotics;   Concentration - efficacy analysis;   Failure / resolution rate of infectious episodes;   Concentration - toxicity analysis
5 Recruiting Fosfomycin Plus Imipenem for Treatment of Infective Endocarditis
Condition: Infective Endocarditis
Interventions: Drug: Fosfomycin and imipenem;   Drug: Vancomycin
Outcome Measures: Proportion of patients with negative blood cultures.;   Toxicity due to treatment
6 Recruiting Pharmacokinetics of Beta-lactam in Patients With Infective Endocarditis
Condition: Infective Endocarditis
Intervention:
Outcome Measure: Blood-plasma concentration of Beta-lactam antibiotics
7 Unknown  Autoantibodies and Clinical Symptoms in Infective Endocarditis Patients
Condition: Infective Endocarditis
Intervention:
Outcome Measure:
8 Recruiting CopenHeart IE - Integrated Rehabilitation of Patients Treated for Infective Endocarditis
Condition: Infective Endocarditis
Interventions: Other: Integrated rehabilitation;   Other: Usual follow-up
Outcome Measures: Change in Mental component scale;   Change in physical capacity
9 Not yet recruiting Pharmaceutical Consultation at Hospital Discharge and Adherence to Anti-Infective Treatment
Condition: Infection
Interventions: Other: Pharma consult;   Other: Routine care
Outcome Measures: The presence/absence of treatment non-adherence;   Delivery of anti-infectious therapy by the pharmacy (yes/no);   Number of anti-infectious drug units dispensed by the pharmacy / number of anti-infections drug units prescribed;   Number of premature discontinuations of anti-Infective therapies / the prescribed number of anti-Infective treatments;   Number of anti-infectious drug units taken by the patient (self-declaration) / number of anti-infections drug units prescribed;   Quiz on anti-Infective therapy comprehension;   Socio-demographic characteristics;   Test for measuring overall compliance (MAQ);   Satisfaction Questionnaire concerning pharmaceutical consultation
10 Recruiting Observational Evaluation of Infective Risk in Myelodysplastic Syndrome Patients
Condition: Myelodysplastic Syndrome
Intervention: Drug: Antibiotic and antifungal drugs
Outcome Measures: Number of infectious events in myelodysplastic syndrome patients;   Number of MDS patients with a febrile event treated with antibiotic, antifungal and antiviral therapy;   Level of neutropenia;   Number of patients who recover from infection;   Number of patients recovered from infection out of the total of patients with documented infection during the observational period;   Number of patients who don't develop bacterial infection;   Number of patient who don't develop fungal infection;   Number of patient who don't develop viral infection;   Number of patients that needed granulocyte growth factors;   Number of patients that needed iron sequestrating therapy caused by iron overload;   Length of the hospitalization;   Weeks of MDS suspension treatment;   Number of patients responding to therapy according to the administered treatment;   Number of MDS patients alive;   Number of patients without MDS progression;   Need for hospitalization;   Level transfusion dependence;   Level of MDS subtype;   Level of risk of International Prognostic Scoring System (IPSS);   Level of International Prognostic Scoring System (IPSS)-revised;   Level of iron overload
11 Unknown  Duration of Antibiotics in Infective Exacerbations of Cystic Fibrosis
Condition: Cystic Fibrosis
Interventions: Drug: Ceftazidime;   Drug: Tobramycin;   Drug: Meropenem
Outcome Measures: Treatment failure at completion of antibiotic course;   Time to next exacerbation;   Change in Spirometry;   Change in inflammatory markers;   Change in sputum bacteriology;   Adverse effects of study antibiotics;   Quality of life scores;   Change in nutritional status
12 Unknown  Oral Anti-Infective Agent for Esophageal Anastomotic Leakage
Condition: Anastomotic Leakage
Interventions: Drug: Mycostatin oral suspension;   Other: Water
Outcome Measures: all cause anastomotic leakage;   Time variation of starting oral feeding and hospital stay
13 Recruiting The Effect of Long-Acting Mesalamine on Post-Infective Irritable Bowel Syndrome- A Pilot Study
Condition: Irritable Bowel Syndrome
Interventions: Drug: Mesalamine;   Drug: Placebo
Outcome Measure: Change from baseline in gastrointestinal symptoms and IBS specific quality of life after an 8 week treatment period
14 Recruiting The Effect of Sodium Bicarbonate on Postoperative Renal Function in Infective Endocarditis Patients Undergoing Open Heart Surgery
Condition: Acute Kidney Injury
Interventions: Drug: sodium bicarbonate;   Drug: Saline
Outcome Measure: Comparison of the incidence of postoperative acute kidney injury in patients with or without sodium bicarbonate
15 Unknown  Bacterial Vaginosis Screening and Treatment to Reduce Infective Complications, Abortion and Preterm Delivery
Conditions: Vaginosis, Bacterial;   Abortion, Spontaneous;   Premature Birth
Intervention: Device: VS Sense
Outcome Measure: Does screening for BV using VS-SENSE in pregnant women with h/o preterm delivery or with premature contractions, and treatment will reduce or prevent Late miscarriage, preterm birth, preterm PROM, chorioamnionitis, and postpartum endometritis.
16 Recruiting The Bacteriuria in Renal Transplantation (BiRT) Study: A Trial Comparing Antibiotics Versus no Treatment in the Prevention of Symptomatic Urinary Tract Infection in Kidney Transplant Recipients With Asymptomatic Bacteriuria
Conditions: Asymptomatic Bacteriuria;   Bacteriuria;   Urinary Tract Infections;   Kidney Transplantation
Intervention: Other: Anti-Infective Agents
Outcome Measures: cumulative incidence of a first episode of symptomatic urinary tract infection;   incidence of a first episode of pyelonephritis;   clearance of asymptomatic bacteriuria;   occurrence of new episodes of asymptomatic bacteriuria;   graft function/graft survival;   incidence of graft rejection;   patient survival;   utility of a control urine culture for diagnosis of asymptomatic bacteriuria in kidney transplant recipients;   level of antimicrobial resistance in bacteria responsible for symptomatic urinary tract infections;   total number of days of antimicrobial therapy;   cost of antimicrobial treatment for asymptomatic bacteriuria and symptomatic urinary tract infection;   number of hospitalizations for asymptomatic bacteriuria and symptomatic urinary tract infection treatment;   total number of symptomatic urinary tract infections in both groups
17 Recruiting 2012_PharmacoCRRT-study:Pharmacokinetics of Anti-Infectives /Antibiotics in Critically Ill Patients in Need of Continuous Renal Replacement Therapy (CRRT)
Conditions: Critically Ill;   Acute Renal Failure;   Acute Kidney Injury
Intervention:
Outcome Measure: Sub-therapeutic levels of measured antiinfectiva
18 Unknown  Va-Sense - Bacterial Vaginosis Once A Week Screening And Treatment To Reduce Infective Complications, Abortion And Preterm Delivery In Pregnant Women With Previous Preterm Delivery
Conditions: Vaginal Infections;   Bacterial Vaginosis;   Late Miscarriage;   Preterm Birth;   Preterm Premature Rupture of Membranes
Intervention: Device: VA-SENSE
Outcome Measure: Incidence of preterm birth, gestational week at delivery.
19 Recruiting The Asia Cornea Society Infectious Keratitis Study
Condition: Corneal Ulcer
Intervention:
Outcome Measures: Resolution of infectious keratitis;   Number of acute surgical interventions required.;   Visual acuity outcome of management.
20 Recruiting Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens
Conditions: Complicated Urinary Tract Infection,;   Complicated Intra-abdominal Infection
Interventions: Drug: Ceftazidime - Avibactam ( CAZ-AVI);   Drug: Best Available Therapy;   Drug: Metronidazole
Outcome Measures: The proportion of patients with clinical cure at the Test of Cure visit in the microbiological intent-to-treat (mMITT) analysis set.;   The proportion of patients with clinical cure in the microbiological modified intent to treat analysis set.;   The proportion of patients with clinical cure in the extended microbiologically evaluable analysis set;   The proportion of patients with clinical cure by pathogen (eg, E. coli, Klebsiella spp., Pseudomonas aeruginosa) in the microbiological modified intent to treat analysis set.;   The proportion of patients with clinical cure by resistance mechanism (eg, Klebsiella pneumoniae carbapenemase producer, Extended spectrum β lactamase producer) in the microbiological modified intent to treat analysis set.;   The proportion of patients with clinical cure by entry diagnosis (complicated intra-abdominal infection/complicated urinary tract infection) in the microbiological modified intent to treat analysis set.;   The proportion of patients with clinical cure by pathogen (eg, E. coli, Klebsiella spp., Pseudomonas aeruginosa) in the extended microbiologically evaluable analysis set.;   The proportion of patients with clinical sure by resistance mechanism (eg, Klebsiella pneumoniae carbapenemase producer, Extended spectrum β lactamase producer) in the extended microbiologically evaluable analysis set.;   The proportion of patients with clinical cure by entry diagnosis (complicated intra-abdominal infection/complicated urinary tract infection) in the extended microbiologically evaluable analysis set.;   The proportion of patients with clinical cure by previously failed treatment class (eg, quinolone, β lactam/β lactamase inhibitor, third- or fourth generation cephalosporin, carbapenem), in the microbiological modified intent to treat analysis set.;   The proportion of patients with clinical cure by previously failed treatment class (eg, quinolone, β lactam/β lactamase inhibitor, third- or fourth generation cephalosporin, carbapenem) in the extended microbiologically evaluable analysis set.;   The proportion of patients with favorable per-pathogen microbiological response in the microbiological modified intent to treat analysis set.;   The proportion of patients with favorable per-pathogen microbiological response in the extended microbiologically evaluable analysis set;   The proportion of patients with a favorable per-patient microbiological response in the microbiological modified intent to treat analysis set.;   The proportion of patients with a favorable per-patient microbiological response in the extended microbiologically evaluable analysis set;   The proportion of patients with a favorable microbiological response by resistance mechanism (eg, Klebsiella pneumoniae carbapenemase producer, Extended spectrum β lactamase producer) in the microbiological modified intent to treat analysis set.;   The proportion of patients with a favorable microbiological response by resistance mechanism (eg, Klebsiella pneumoniae carbapenemase producer, Extended spectrum β lactamase producer) in the extended microbiologically evaluable analysis set;   The proportion of favorable per-pathogen microbiologic response by minimum inhibitory concentration in the microbiological modified intent to treat analysis set.;   The proportion of favorable per-pathogen microbiologic response by minimum inhibitory concentration in the extended microbiologically evaluable analysis set;   The number of patients that change or discontinue treatment by reason in the microbiological modified intent to treat population analysis set;   The 28-day mortality rate in the microbiological modified intent to treat analysis set;   The 28-day mortality rate in the extended microbiologically evaluable analysis set.;   Profile of pharmacokinetic (PK): maximum plasma concentration (Cmax);   Profile of pharmacokinetic (PK): minimum plasma concentration (Cmin);   Profile of pharmacokinetic (PK): area under plasma concentration time curve at study state (AUC ss);   Profile of pharmacokinetic (PK): elimination half-life (t ½);   Safety and tolerability profile by incidence and severity of adverse events and serious adverse events, vital signs, clinical laboratory tests, ECGs and physical exams

These studies may lead to new treatments and are adding insight into Infective etiology and treatment.

A major focus of Infective research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Infective